Guru Sonpavde
Associate Professor of Medicine at Harvard Medical School
Biography
Harvard Medical School
Guru P. Sonpavde, MD is the director of the bladder cancer program at Dana-Farber Cancer Institute and is on the faculty of Harvard Medical School. He completed his medical oncology fellowship at Indiana University. His primary focus is on clinical trials to develop new drugs and combinations to treat urologic cancers, particularly bladder cancer. He also has led translational projects and developed prognostic classifications and endpoints focused on bladder cancer. He is a member of the Genitourinary Committee of Southwest Oncology Group and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Steering Committee.
Clinical Interests
- Bladder cancer
- Novel therapies
- Penile cancer
- Prostate cancer
- Renal cancer
- Testicular cancer
Education
- Indiana university medical center - Fellowship, Fellowship Hematology- Oncology 1995 - 1999
- Nassau university medical center - resident, internal medicine 1992 - 1995
- Christian medical college vellore - MBBS, Medical school 1984 - 1990
- Kendriya Vidyalaya, CLRI (Adyar) - High school, Biology/Biological Sciences, General 1980 - 1984
Videos
Dr. Sonpavde on Immunotherapy Combination Studies in Urothelial Carcinoma
Dr. Guru Sonpavde, Dana-Farber Cancer Institute, USA
Dr. Guru Sonpavde on Bladder Cancer | Dana-Farber Cancer Institute
Critical Trial Review in GU Oncology, interview with Guru Sonpavde MD
ctDNA analysis may help to personalize metastatic urothelial carcinoma treatments | Guru Sonpavde
Dr. Sonpavde on Remaining Questions With Immunotherapy in Bladder Cancer
Dana-Farber Cancer Institute: Guru Sonpavde, MD at ASCO GU21 (bladder cancer)
Bladder cancer research at ESMO 2021
Dr. Sonpavde on Neoadjuvant Immunotherapy in Bladder Cancer
Dr. Sonpavde on the Potential for Neoadjuvant Immunotherapy in Bladder Cancer
FGFR Inhibitors in Bladder Cancer
Dr. Guru Sonpavde
Dana-Farber Cancer Institute: Guru Sonpavde, MD at ASCO GU21 (urothelial carcinoma)
Dr. Sonpavde on the Role of Durvalumab in Platinum-Refractory Bladder Cancer
Adjuvant immunotherapy for MIBC: patient case with Guru Sonpavde & Andrew Schmidt
Read about executive education
Other experts
Popular Courses
Looking for an expert?
Contact us and we'll find the best option for you.